In 2014, the U.S. National Institutes of Health launched a program called the Undiagnosed Disease Network. The New England Journal of Medicine published a study looking at the results of the network.

An experimental GlaxoSmithKline vaccine could prevent tuberculosis developing in half of those who receive it, making the vaccine potentially the first new shot against the global killer in a century.

Doctors in Kentucky reported that two of four paralyzed patients were able to walk again with limited assistance after treatment with electrical stimulation to the portion of the spinal cord cut off from the brain, combined with intense physical therapy.

AstraZeneca announced that the U.S. Food and Drug Administration accepted a supplemental New Drug Application for the use of Tagrisso (osimertinib) – a third-generation, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor with clinical activity against central nervous system metastases – in the first-line treatment of patients with metastatic non-small cell lung cancer whose tumors have EGFR mutations.

Philadelphia-based Spark Therapeutics, with its partner Pfizer, published interim data from its Phase I/II clinical trial of a gene therapy for hemophilia B in The New England Journal of Medicine.

Checkpoint inhibitors have become popular treatments for cancers, but a New England Journal of Medicine article may give physicians pause before prescribing them.

Johnson & Johnson’s and AbbVie’s cancer drug Imbruvica significantly reduced the risk of death and disease progression compared with chemotherapy in previously untreated patients with a type of leukemia in a late stage study, paving the way for an expanded approval of the medicine. In the trial of 269 patients aged 65 and older with […]